UK Oxford-AstraZeneca CVID vaccine trial stopped Coronavirus Epidemic News

The University of Oxford said the trial had “no security concerns” but would wait for additional data before reopening.

The University of Oxford said on Tuesday it had suspended a small UK trial testing the COVID-19 vaccine with AstraZeneca in children and adolescents as it waited for more information on the problem of rare blood clots in adults.

The university, which accidentally assisted in the development of the vaccine, said in a statement that the test had “no safety concerns”, but acknowledged the possible link between clots and said it was awaiting additional information from the UK’s Medicines and Health Care Product Regulatory. MHRA).

“Parents and children should continue to participate in all scheduled visits and contact trial sites if they have any questions.”

This is the latest drama to hit AstraZeneca, which has been embroiled in controversy over its failure to deliver the EU’s promised dose and Jab’s effectiveness and safety profile.

MHRA, one of the world’s leading MHRA organizations, analyzed real-world data from the AstraZeneca rollout to see if there was any specific link between a rare form of JAB and blood clots, initially after news of the case broke in Norway and continental Europe.

The MHRA reported over the weekend that of the 17 million doses administered in Britain, 30 had blood clotting disease, seven were fatal.

The European Medicines Agency (EMA) said on Tuesday that it had “not yet reached a decision and is currently under review”.

EU Health Commissioner Stella Kiriakaids later said the agency was expected to make its decision “late Wednesday night” and added that she had “close contact” with the EMA.

The latest push for the vaccine, which was once hailed as a milestone in the fight against the epidemic, came after several countries banned its use in light of post-inoculation treatment reports. [File: Kai Pfaffenbach/REUTERS]

Both Germany and France have restricted the use of the vaccine in the elderly, with younger recipients at greater risk of developing clots.

‘Benefit beyond risk’

The UK and vaccine developers have so far resisted any restrictions on use, saying there is no evidence of a link.

Adam Finn, a professor of pediatrics at the University of Bristol in the UK, said the benefits outweigh the risks.

“We need to know more about the victims and understand exactly how the illnesses happened,” he said.

He added, “If you are currently being given a dose of the Oxford-Astrageneca vaccine, you will go down if you do not take the vaccine and your chances of survival increase.”

The World Health Organization said on Tuesday that there was no reason to change its assessment that the benefits of the AstraZeneca vaccine against COVID-19 outweigh any risks.

Spots with governments across Europe about production, supply, potential side effects, and the qualities of the vaccine have plagued Anglo-Swedish drug manufacturers for months.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *